CSL Bulls See Valuation Support Despite Challenges -- Market Talk

Dow Jones

04/16

0108 GMT - CSL's bulls at UBS continue to see valuation support for the stock despite challenges from pricing, demand, and energy costs. The investment bank's analysts keep a buy rating on the vaccine and blood-products manufacturer, citing structurally sound demand for immunoglobulin and unchanged medium-term growth assumptions. They tell clients in a note that temporary oversupply in the U.S. is weighing on pricing but expect subdued plasma collections to help address this. Less positively, they see little evidence of the recovery in Chinese demand necessary to improve albumin sales growth. Cost inflation is also an emerging headwind, they add. UBS cuts its target price by 13% to A$205.00. Shares are down 2.1% at A$136.58. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 15, 2026 21:08 ET (01:08 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2627960254"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627960254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627960254?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 09:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627960254","market":"fut","top_or_hot":-1,"title":"CSL Bulls See Valuation Support Despite Challenges -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0108 GMT - CSL's bulls at UBS continue to see valuation support for the stock despite challenges from pricing, demand, and energy costs. The investment bank's analysts keep a buy rating on the vaccine and blood-products manufacturer, citing structurally sound demand for immunoglobulin and unchanged medium-term growth assumptions. They tell clients in a note that temporary oversupply in the U.S. is weighing on pricing but expect subdued plasma collections to help address this. Less positively, they see little evidence of the recovery in Chinese demand necessary to improve albumin sales growth. Cost inflation is also an emerging headwind, they add. UBS cuts its target price by 13% to A$205.00. Shares are down 2.1% at A$136.58. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 15, 2026 21:08 ET (01:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSL Bulls See Valuation Support Despite Challenges -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSL Bulls See Valuation Support Despite Challenges -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-16 09:08</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0108 GMT - CSL's bulls at UBS continue to see valuation support for the stock despite challenges from pricing, demand, and energy costs. The investment bank's analysts keep a buy rating on the vaccine and blood-products manufacturer, citing structurally sound demand for immunoglobulin and unchanged medium-term growth assumptions. They tell clients in a note that temporary oversupply in the U.S. is weighing on pricing but expect subdued plasma collections to help address this. Less positively, they see little evidence of the recovery in Chinese demand necessary to improve albumin sales growth. Cost inflation is also an emerging headwind, they add. UBS cuts its target price by 13% to A$205.00. Shares are down 2.1% at A$136.58. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 15, 2026 21:08 ET (01:08 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4086","symbol_name":"建築產品","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2627960254","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627960254","pubTimestamp":1776301680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0108 GMT - CSL's bulls at UBS continue to see valuation support for the stock despite challenges from pricing, demand, and energy costs. The investment bank's analysts keep a buy rating on the vaccine and blood-products manufacturer, citing structurally sound demand for immunoglobulin and unchanged medium-term growth assumptions. They tell clients in a note that temporary oversupply in the U.S. is weighing on pricing but expect subdued plasma collections to help address this. Less positively, they see little evidence of the recovery in Chinese demand necessary to improve albumin sales growth. Cost inflation is also an emerging headwind, they add. UBS cuts its target price by 13% to A$205.00. Shares are down 2.1% at A$136.58. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4086":"建筑产品","CSL.AU":"CSL LIMITED","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","BK7067":"生物科技","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","CSL":"卡莱尔伙伴","BK7511":"ESG概念","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK7501":"新冠治疗股","BK7508":"医药生物股"},"translate_title":"尽管面临挑战，CSL多头仍看到估值支撑——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1.5},"content_text":"0108 GMT - CSL's bulls at UBS continue to see valuation support for the stock despite challenges from pricing, demand, and energy costs. The investment bank's analysts keep a buy rating on the vaccine and blood-products manufacturer, citing structurally sound demand for immunoglobulin and unchanged medium-term growth assumptions. They tell clients in a note that temporary oversupply in the U.S. is weighing on pricing but expect subdued plasma collections to help address this. Less positively, they see little evidence of the recovery in Chinese demand necessary to improve albumin sales growth. Cost inflation is also an emerging headwind, they add. UBS cuts its target price by 13% to A$205.00. Shares are down 2.1% at A$136.58. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 15, 2026 21:08 ET (01:08 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}